BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

PALO ALTO, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced its financial results for the third quarter ended September 30, 2025, and provided business updates.

Commercial Progress:As of October 25, 2025, 5,259 unique patient prescriptions have been written by 1,355 unique prescribers since FDA approval in November 2024. The third quarter revenue totaled $120.7 million, comprised of $108.1 million of U.S. Attruby net product revenue, $4.3 million from royalty revenue, and $8.3 million in license and services revenue.

“Attruby’s first year on the market has been remarkable, with continued growth across all market segments and strong physician adoption that reflects both the differentiated clinical profile and the trust we’re earning within the community. We’re seeing meaningful momentum where prescribers are not only initiating more patients on therapy but continuing treatment, underscoring Attruby’s real-world impact,” said Matt Outten, Chief Commercial Officer of BridgeBio. “Importantly, this launch has also given us an invaluable blueprint for how we bring best-in-class medicines to patients with genetic diseases. With the promising results seen in BBP-418 for LGMD2I/R9 and encaleret for ADH1, we are building on a proven commercial foundation to ensure these communities, each living with urgent, unmet needs, have timely access to transformative therapies and we will apply the playbook we’ve developed to prepare for our next potential approvals.”

“Attruby’s strong commercial performance continues to validate our model, delivering a potential best-in-class medicine to patients who were historically overlooked and building meaningful momentum across all market segments,” said Neil Kumar, Ph.D., founder and CEO of BridgeBio. “We are now seeing that same success echoed in our pipeline with home-run data in both ADH1 and LGMD2I/R9, and we continue to advance one of the broadest and fastest-moving portfolios in genetic medicine. With achondroplasia data expected in 2026, enrollment nearing completion for the Phase 2 potion of the hypochondroplasia study, and registrational studies for encaleret in chronic hypoparathyroidism and pediatric ADH1 planned next year, we are not slowing down and continue to be impatient for patients. These milestones reflect our growing scalability and strengthen our conviction that BridgeBio is only beginning to show what’s possible as we evolve into a durable, multi-medicine company built for patients with genetic diseases for decades to come.”

Cash, cash equivalents and marketable securities totaled $645.9 million as of September 30, 2025, compared to cash and cash equivalents of $681.1 million as of December 31, 2024. The $35.2 million decrease is primarily attributable to net cash used in operating activities of $389.5 million for the nine months ended September 30, 2025, the repayment of the Company’s previous term loan under its credit facility (including prepayment fees) of $459.0 million in February 2025, and the repurchase of common stock of $48.3 million using proceeds from the 2031 Notes in February 2025. These outflows were partially offset by net proceeds of $563.0 million from the issuance of the 2031 Notes in February 2025 and net proceeds of $297.0 million from the execution of the Royalty Interest Purchase and Sale Agreement with HealthCare Royalty, a related party, and Blue Owl Capital in June 2025.

Total revenues, net for the three months ended September 30, 2025, were $120.7 million compared to $2.7 million for the same period in the prior year. The $118.0 million increase was primarily driven by a $108.1 million increase in net product revenue from the Company's commercial product, Attruby, a $5.6 million increase in license and services revenue, and a $4.3 million increase in royalty revenue earned on net product sales of BEYONTTRA in the EU and Japan.

Total revenues, net for the nine months ended September 30, 2025, were $347.9 million compared to $216.0 million for the same period in the prior year. The $131.9 million increase was primarily driven by a $216.4 million increase in net product revenue from the Company's commercial product, Attruby, and a $6.1 million increase in royalty revenue earned on net product sales of BEYONTTRA in the EU and Japan. These increases were partially offset by a $90.6 million decrease in license and services revenue, reflecting the timing of recognition of upfront payments from the Company's exclusive license agreements with collaboration partners as well as regulatory-related milestones recognized upon the approval of BEYONTTRA in the EU and pricing approval in Japan.

Operating costs and expenses for the three months ended September 30, 2025 were $265.9 million compared to $194.5 million for the same period in the prior year. The $71.4 million increase was primarily driven by a $68.8 million increase in selling, general and administrative (“SG&A”) expenses largely reflecting the Company’s investments in support of the commercial launch and ongoing activities of Attruby, and a $6.0 million increase in total cost of revenues, primarily due to the cost of Attruby products sold. These increases were partially offset by a $7.6 million decrease in research and development ("R&D") expenses as a result of the Company's reprioritization of its R&D programs.

Operating costs and expenses for the nine months ended September 30, 2025 were $731.7 million compared to $583.0 million for the same period in the prior year. The $148.7 million increase was primarily driven by a $179.0 million increase in SG&A largely reflecting the Company’s investments to support the commercial launch and ongoing activities of Attruby, and an $11.1 million increase in total cost of revenues, primarily due to the cost of Attruby products sold. The increases were partially offset by a $40.6 million decrease in R&D expenses as a result of the Company's reprioritization of its R&D programs.

Stock-based compensation expenses included in operating costs and expenses for the three months ended September 30, 2025 were $35.3 million, of which $21.9 million is included in SG&A expenses, $12.3 million is included in R&D expenses, $0.7 million is included in restructuring impairment and related charges, and $0.4 million is included in cost of goods sold. Stock-based compensation expenses included in operating costs and expenses for the same period in 2024 were $27.1 million, of which $15.0 million was included in SG&A expenses and $12.1 million was included in R&D expenses.

Stock-based compensation expenses included in operating costs and expenses for the nine months ended September 30, 2025 were $102.0 million, of which $63.1 million is included in SG&A expenses, $37.5 million is included in R&D expenses, $0.8 million is included in restructuring impairment and related charges, and $0.6 million is included in cost of goods sold. Stock-based compensation expenses included in operating costs and expenses for the same period in the prior year were $77.4 million, of which $47.5 million was included in SG&A expenses and $29.8 million was included in R&D expenses, and $0.1 million was included in restructuring, impairment and related charges.

Total other income (expense), net for the three and nine months ended September 30, 2025, was $(41.3) million and $(153.9) million, respectively, compared to $27.5 million and $91.0 million, respectively, for the same periods in the prior year.

The change in total other income (expense), net of $68.8 million for the three months ended September 30, 2025, compared to 2024 was primarily due to a decrease in gain on deconsolidation of subsidiaries of $52.0 million, and an increase in noncash interest expense on deferred royalty obligations of $36.4 million, partially offset by a decrease in interest expense of $11.3 million, and an increase in other income of $7.8 million related to noncash income from the Company's equity method investment.

The change in total other income (expense), net of $244.9 million for the nine months ended September 30, 2025, compared to 2024 was primarily due to a decrease in gain on deconsolidation of subsidiaries of $178.3 million, an increase in noncash interest expense on deferred royalty obligations of $86.5 million, and an increase in net loss from equity method investments of $37.1 million; partially offset by a decrease in interest expense of $28.0 million, an increase in other income of $11.1 million for the change in fair value of the embedded derivative liability component of the Company's deferred royalty obligation, an increase in other income of $7.5 million for services provided under the transition service agreements, and an increase in other income of $7.8 million related to noncash income from the Company's equity method investment.

For the three and nine months ended September 30, 2025, the Company recorded a net loss attributable to common stockholders of BridgeBio of $182.7 million and $532.1 million, respectively, compared to $162.0 million and $270.7 million, respectively, for the same periods in the prior year.

For the three and nine months ended September 30, 2025, the Company reported a net loss per share of $0.95 and $2.79, respectively, compared to $0.86 and $1.46, respectively, for the same periods in the prior year.

Webcast InformationBridgeBio will host its quarterly earnings call and simultaneous webcast on Wednesday, October 29th 2025 at 4:30 pm ET. To access the live webcast of BridgeBio’s presentation, please visit the “Events” page within the Investors section of the BridgeBio website athttps://investor.bridgebio.com/news-and-events/event-calendaror register online using the following link,https://events.q4inc.com/attendee/108071157. A replay of the conference call and webcast will be archived on the Company’s website and will be available for at least 30 days following the event.

INDICATIONAttruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATIONAdverse ReactionsDiarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

About BridgeBio Pharma, Inc.BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visitbridgebio.comand follow us onLinkedIn,X,Facebook,Instagram, andYouTube.

BridgeBio Pharma, Inc. Forward-Looking StatementsThis press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “remains,” “seeks,” “should,” “will,” and variations of such words or similar expressions, or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.

These forward-looking statements, including express and implied statements relating to the commercial success of Attruby and BEYONTTRA, including the potential for Attruby to become the standard of care for ATTR-CM and efficacy and safety of Attruby for ATTR-CM patients; the topline results from FORTIFY, the Phase 3 clinical trial for BBP-418 for LGMD2I/R9 and the Company’s plan to submit a New Drug Application for BBP-418 to the FDA in the first half of 2026; the topline results from CALIBRATE, the Phase 3 clinical trial for encaleret in patients with ADH1 and the Company’s plan to initiate clinical trial of encaleret in pediatric ADH1 in 2026 and to submit a New Drug Application for encaleret to the FDA in the second quarter of 2026 and a Marketing Authorization Application to the European Medicines Agency; the efficacy, safety and the clinical and therapeutic potential of BBP-418 and encaleret; the status and next expected milestone for the Company’s other clinical trials, including the anticipated timing for the topline results for PROPEL 3; the Registrational study plan for encaleret for chronic hypoparathyroidism; and the anticipated timing for enrollment completion and data release for ACCEL 2/3; the potential for BBP-418 to become the first approved treatment for LGMD2I/R9; the potential for encaleret to become the first approved treatment for ADH1; the potential for infigratinib to become a new treatment for children with achondroplasia and hypochondroplasia; the Company’s anticipated funding of its current operations; and the Company’s expectations regarding reaching regulatory and commercial milestones, among others, reflect our current views about our plans, intentions, expectations and strategies, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved.

Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, initial and ongoing data from our preclinical studies and clinical trials not being indicative of final data, the potential size of the target patient populations our product candidates are designed to treat not being as large as anticipated, the design and success of ongoing and planned clinical trials, future regulatory filings, approvals and/or sales, despite having ongoing and future interactions with the FDA or other regulatory agencies to discuss potential paths to registration for our product candidates, the FDA or such other regulatory agencies not agreeing with our regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted, the continuing success of our collaborations, our ability to obtain additional funding, including through less dilutive sources of capital than equity financings, potential volatility in our share price, the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and in Israel and the Gaza Strip, and increasing rates of inflation and changing interest rates, on business operations and expectations, as well as those risks set forth in the Risk Factors section of our most recent Annual Report on Form 10-K, and the Company’s other subsequent filings with the U.S. Securities and Exchange Commission. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.